🇺🇸 FDA
Patent

US 11739101

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

granted A61PA61P31/12A61P35/00

Quick answer

US patent 11739101 (Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof) held by NURIX THERAPEUTICS, INC. expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61P, A61P31/12, A61P35/00, A61P37/02